Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-01-18
2011-01-18
Wen, Sharon (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S388100, C530S388150
Reexamination Certificate
active
07872106
ABSTRACT:
Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
REFERENCES:
patent: 4331647 (1982-05-01), Goldenberg
patent: 4376110 (1983-03-01), David et al.
patent: 4411993 (1983-10-01), Gillis
patent: 4427115 (1984-01-01), Laipply
patent: 4543439 (1985-09-01), Frackelton, Jr. et al.
patent: RE32011 (1985-10-01), Zimmerman et al.
patent: 4837440 (1989-06-01), Burtscher et al.
patent: 4902614 (1990-02-01), Wakabayashi et al.
patent: 5070108 (1991-12-01), Margolis
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5399363 (1995-03-01), Liversidge et al.
patent: 5453492 (1995-09-01), Butzow et al.
patent: 5466468 (1995-11-01), Schneider et al.
patent: 5543158 (1996-08-01), Gref et al.
patent: 5552157 (1996-09-01), Yagi et al.
patent: 5565213 (1996-10-01), Nakamori et al.
patent: 5567434 (1996-10-01), Szoka, Jr.
patent: 5627052 (1997-05-01), Schrader et al.
patent: 5641515 (1997-06-01), Ramtoola et al.
patent: 5698426 (1997-12-01), Huse
patent: 5738868 (1998-04-01), Shinkarenko et al.
patent: 5780263 (1998-07-01), Hastings et al.
patent: 5795587 (1998-08-01), Gao et al.
patent: 5811238 (1998-09-01), Stemmer et al.
patent: 5830721 (1998-11-01), Stemmer et al.
patent: 5837458 (1998-11-01), Minshull et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 6054561 (2000-04-01), Ring
patent: 6057421 (2000-05-01), Muller et al.
patent: 6117911 (2000-09-01), Grainger et al.
patent: 6133426 (2000-10-01), Gonzalez et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6207153 (2001-03-01), Dan et al.
patent: 6395511 (2002-05-01), Brunkow et al.
patent: 6489445 (2002-12-01), Brunkow et al.
patent: 6495736 (2002-12-01), Brunkow et al.
patent: 6703199 (2004-03-01), Koide
patent: 6803453 (2004-10-01), Brunkow et al.
patent: 6806055 (2004-10-01), Berman et al.
patent: 6815201 (2004-11-01), Pinter
patent: 6818748 (2004-11-01), Fulton et al.
patent: 7192583 (2007-03-01), Brunkow et al.
patent: 7226902 (2007-06-01), Winkler et al.
patent: 2003/0165410 (2003-09-01), Taylor
patent: 2003/0186915 (2003-10-01), Pan et al.
patent: 2003/0022904 (2003-12-01), Sutherland et al.
patent: 2004/0009535 (2004-01-01), Brunkow et al.
patent: 2004/0023356 (2004-02-01), Krumlauf et al.
patent: 2004/0058321 (2004-03-01), Brunkow et al.
patent: 2004/0141875 (2004-07-01), Doshi
patent: 2004/0146888 (2004-07-01), Paszty et al.
patent: 2004/0158045 (2004-08-01), Brunkow et al.
patent: 2005/0014650 (2005-01-01), Seitz et al.
patent: 2005/0106683 (2005-05-01), Winkler et al.
patent: 2005/0238646 (2005-10-01), Ledbetter et al.
patent: 2006/0233801 (2006-10-01), Brunkow et al.
patent: 2007/0072797 (2007-03-01), Robinson et al.
patent: 2007/0110747 (2007-05-01), Paszty et al.
patent: 2007/0292444 (2007-12-01), Krumlauf et al.
patent: 2008/0182788 (2008-07-01), Brunkow et al.
patent: 2008/0234219 (2008-09-01), Brunkow et al.
patent: 2009/0074763 (2009-03-01), Padhi et al.
patent: 4-141095 (1992-05-01), None
patent: WO-91/13152 (1991-09-01), None
patent: WO-92/02551 (1992-02-01), None
patent: WO-92/06693 (1992-04-01), None
patent: WO-95/30003 (1995-11-01), None
patent: WO-98/21335 (1998-05-01), None
patent: WO-99/03996 (1999-01-01), None
patent: WO-99/06554 (1999-02-01), None
patent: WO-99/15556 (1999-04-01), None
patent: WO-00/32773 (2000-06-01), None
patent: WO-00/75317 (2000-12-01), None
patent: WO-01/64885 (2001-09-01), None
patent: WO-01/92308 (2001-12-01), None
patent: WO-01/98491 (2001-12-01), None
patent: WO-2004/098491 (2001-12-01), None
patent: WO-02/24888 (2002-03-01), None
patent: WO-03/050513 (2003-06-01), None
patent: WO-03/087763 (2003-10-01), None
patent: WO-03/106657 (2003-12-01), None
patent: WO-2004/082608 (2004-09-01), None
patent: WO-2005/003158 (2005-01-01), None
patent: WO-2005/014650 (2005-02-01), None
patent: WO-2006/102070 (2006-09-01), None
patent: WO-2006/119062 (2006-11-01), None
patent: WO-2006/119107 (2006-11-01), None
patent: WO-2008/061013 (2008-05-01), None
patent: WO-2008/115732 (2008-09-01), None
patent: WO-2008/133722 (2008-11-01), None
patent: WO-2009/039175 (2009-03-01), None
The Merck Manuals Online Medical Library, [online]. Whitehouse Station, NJ: Merck Research Laboratories, 2006-2007. [retrieved on May 6, 2010]. Retrieved from the Internet: <URL: http://www.merck.com/mmpe/print/sec15/ch199/ch199b.html>. Anorexia Nervosa, pp. 1-4.
Anonymous, Amgen presents denosumab and sclerostin antibody data at American Society for Bone and Mineral Research Annual Meeting. Amgen Media Press Release. www.amgen.com/media/media—pr—detail.jsp?releaselD=907028 (2006).
Eli Lilly Statement of Grounds of Appeal, Opposition to European Patent Application No. 1133558 B1, dated Sep. 28, 2009.
Declaration filed in connection with the European Patent EP 1133558 Opposition, Expert opinion of Prof. Dr. Thomas Muller, dated Sep. 23, 2009.
Winkler et al., Osteocyte control of bone formation via sclerostin, a novel BMP antagonist,EMBO J.22(23): 6267-76 (2003).
van Bezooijen et al., Sost/sclerostin, an osteocyte-derived negative regulator of bone formation,Cytokine Growth Factor Rev., 16: 319-27 (2005).
Li et al., Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling,J. Biol. Chem. 280(20): 19883-7 (2005).
Declaration filed in connection with the European Patent EP 1133558 Opposition, Expert opinion of Dr. Walter Sebald, dated Sep. 24, 2009.
Kirsch et al., BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II,EMBO J. 19(13): 3314-24 (2000).
Heinecke et al., Receptor oligomerization and beyond: A case study in bone morphogenetic proteins,BMC Biol. 7: 59 (2009).
Declaration filed in connection with the European Patent EP 1133558 Opposition, Expert opinion of Prof. Dr. Edgar Wingender, dated Sep. 24, 2009.
Mayer et al., Differentiation of osteogenetic cells: Systems and regulators, Z. Orthop., 130: 276-84 (1992)—Abstract Only.
Blum et al., Study plan for German students in the summer of 1998, University Bioinformatik lecture announcement (1998).
Baxevanis (Ed.) et al., Bioinformatics: A practical guide to the analysis of genes and proteins, John Wiley & Sons, Inc. p. 234 (1998).
Bishop (Ed.), Guide to Human Genome Computing, Second Edition, Academic Press, Chapter 1: Introduction to human genome computer via the world wide web, pp. 1-14 (2003).
Declaration filed in connection with the European Patent EP 1133558 Opposition, Expert opinion of Dr. Auristela Freire de Paes Alves, Ph.D., dated Sep. 9, 2009.
Eli Lilly, Biacore experiment comparison results, Setup assay to measure BMP binding to captured SOST, referenced on p. 41 of reference C193 dated Sep. 28, 2009.
Mayer et al., Differentiation of osteogenetic cells: Systems and regulators, Z. Orthop., 130: 276-84 (1992)—Abstract Only.
Albertsen et al., A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21,Nat. Genet. 7: 472-479 (1994).
Alting-Mees et al., Monoclonal antibody expression libraries: a rapid alternative to hybridomas.Strategies in Molecular Biology, 3:1-9 (1990).
Alves et al., Sclerosteosis: A marker of Dutch ancestry?Rev. Bras. Genet.4: 825-34 (1982).
Angel et al., A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody.Mol. Immunol.30(1):105-108 (1993).
Avsian-Kretchmer et al., Comparative genomic analysis of the eight-membered ring cysteine knot-containing bone morphogenetic protein antagonists.Mol. Endocrinol.18: 1-12 (2004).
Babcook et al., A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities.Proc. Natl. Acad. Sci.(USA), 93:7843-7848 (1996).
Baines et al., Purification of Immunoglobulin G (IgG), Methods in Molecular Biology. The Humana Press, Inc. vol. 10, Chapter 8, pp. 79-104 (1992).
Balemans et al., Extracellular Regulation of BMP Signaling in Vertebrates: A cocktail of Modulators.Dev. Biol.250:231-250 (2002).
Balemans et al., Increased bone densi
Graham Kevin
Henry Alistair J.
Latham John
Lawson Alastair
Lu Hsieng S.
Amgen Inc.
Marshall & Gerstein & Borun LLP
UCB Pharma S.A.
Wen Sharon
LandOfFree
Sclerostin-binding antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sclerostin-binding antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sclerostin-binding antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2740971